Are 'great' tweet­ers born? Or can they be made? A con­ver­sa­tion with Adam Feuer­stein.

Ex­change

If you’re a drug de­vel­op­ment pro­fes­sion­al with am­bi­tion, you can’t af­ford to ig­nore Twit­ter. No mat­ter your opin­ion of Twit­ter as a com­pa­ny, the act of tweet­ing is here to say: short, pub­lic, one-to-many com­mu­ni­ca­tion is nev­er be­ing put back in the bot­tle. I’ve writ­ten about this is­sue be­fore, of­fer­ing a list of 300 ac­counts known to tweet bio­phar­ma-re­lat­ed news fastest. Main­tain­ing a good list of fol­lowed ac­counts, con­sum­ing your news di­rect­ly from the source, ex­pos­ing your­self to a di­ver­si­ty of opin­ion out­side your com­fort zone: that’s BioTwit­ter 101, the min­i­mum re­la­tion­ship a drug de­vel­op­er ought to have with so­cial me­dia. There’s no ex­cuse to dis­miss all so­cial me­dia with a wide brush of this doesn’t ap­ply to me. You don’t have to tweet to be good at Twit­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER